A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer

Autor: Patricia Pautier, Nicholas Reed, Geoffrey Hall, Eric Chetaille, Anna Lisyanskaya, Florence Joly, Ignace Vergote, Ana Oaknin, John Green, Muhammad Shoaib, Zanete Zvirbule, Valerijus Ostapenko, Agnès Geniaux, Bohuslav Melichar, Elzbieta Kutarska

ObjectiveAdvanced/metastatic or recurrent endometrial cancer has a poor prognosis. Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this study was to evaluate STS as a therapeutic target in patients with endometrial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10a8404763f1557e0a5600d11896dbc
https://lirias.kuleuven.be/handle/123456789/558056

Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

Autor: Elzbieta Kutarska, Jim Symanowski, Mariusz Bidzińsk, R. Wendel Naumann, Thomas J. Herzog, Binh Nguyen, Reshma A. Rangwala

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 26(9)

ObjectiveThis exploratory analysis evaluated the incidence of adverse events (AEs) by folate receptor (FR) status in the randomized, multicenter, open-label PRECEDENT study in women with platinum-resistant ovarian cancer receiving pegylated liposomal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c6022a5769d7df33ea575c9e0682d06
https://pubmed.ncbi.nlm.nih.gov/27654255

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Autor: Salvatore A. Del Prete, Michael S. Gordon, Sudarshan Sharma, Hua Liu, Ursula A. Matulonis, Xiaofei Zhou, Sharad A. Ghamande, Russell J. Schilder, Hadi Danaee, Howard Fingert, Isabelle Ray-Coquard, Elzbieta Kutarska

Publikováno v: Gynecologic oncology. 127(1)

Objectives Aurora A kinase (AAK), a key mitotic regulator, is implicated in the pathogenesis of several tumors, including ovarian cancer. This single-arm phase II study assessed single-agent efficacy and safety of the investigational AAK inhibitor ML

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0060c1dcc29af72550c49341bbe39fd
https://pubmed.ncbi.nlm.nih.gov/22772063

Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer

Autor: Binh Nguyen, Elzbieta Kutarska, R. Wendel Naumann, Reshma A. Rangwala, Mariusz Bidziński, James T. Symanowski

Publikováno v: Journal of Clinical Oncology. 31:5572-5572

5572 Background: Vintafolide (EC145), a folic acid/desacetylvinblastine conjugate, binds with high affinity to folate receptors expressed in epithelial ovarian cancers. This analysis evaluated the incidence of adverse events (AEs) by treatment cycle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01b85c6143fc2f2eef6a0ec600659046
https://doi.org/10.1200/jco.2013.31.15_suppl.5572

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

Autor: Naumann RW; R. Wendel Naumann and James T. Symanowski, Levine Cancer Institute, Carolinas Medical Center, Charlotte, NC; Robert L. Coleman, MD Anderson Cancer Center, University of Texas, Houston; Michael G. Teneriello, Texas Oncology, Austin, TX; Robert A. Burger, Fox Chase Cancer Center, Philadelphia, PA; Edward A. Sausville, Greenebaum Cancer Center, University of Maryland, Baltimore, MD; Elzbieta Kutarska, Centrum Onkologii Ziemi Lubelskiej, Lubland; Elzbieta Nowara, Instytut im. Marii Skłodowskiej-Curie, Gliwice, Poland; Sharad A. Ghamande, Georgia Health Sciences University, Augusta, GA; Nashat Y. Gabrail, Gabrail Cancer Center, Canton, OH; Stephen E. DePasquale, Chattanooga's Program in Women's Oncology, Chattanooga, TN; Lucy Gilbert, McGill University Health Centre, Montreal, Quebec, Canada; Robert H. Gersh, Cancer Care Northwest, Spokane, WA; Wael A. Harb, Horizon Oncology Research, Lafayette; Chandra D. Lovejoy, Christopher P. Leamon, David E. Morgenstern, and Richard A. Messmann, Endocyte, West Lafayette, IN; Panagiotis A. Konstantinopoulos, Beth Israel Deaconess Medical Center; and Richard T. Penson, Dana-Farber Cancer Center, Massachusetts General Hospital, Boston, MA., Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Dec 10; Vol. 31 (35), pp. 4400-6. Date of Electronic Publication: 2013 Oct 14.